Connect with us

Technology

FDB Moves Ambient Listening Beyond Notes with AI-Powered Prescribing Agent

Published

on

First commercial deployment of FDB Script Agent™ with Tebra converts ambient encounter dialogue into structured prescriptions for clinician review, grounded in trusted medication intelligence

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2026 /PRNewswire/ — FDB (First Databank, Inc.), the leading provider of clinically robust, AI-enabled medication intelligence that helps healthcare professionals make precise medication decisions and streamline medication workflows, today announced the first commercial deployment of FDB Script Agent™, an AI prescribing agent that turns patient-visit dialogue into structured prescriptions ready for clinician review. The deployment with Tebra, an all-in-one technology platform for independent healthcare practices, brings FDB’s trusted medication intelligence into the ambient clinical workflow with clinical validation and terminology codification rather than simple NLP.

Script Agent uses FDB’s dose-appropriate medication intelligence to transform encounter dialogue into structured, evidence-based prescriptions for clinician review. Clinicians can modify or approve each prescription before it is sent. Due to its clinical grounding, the agent avoids hazards of simple NLP alone and will not stage prescriptions that fall outside normal prescribing practice without a clinician override.

Ambient AI has significantly reduced documentation burden by turning patient conversations into clinical notes, but prescribing often remains a manual task during or after the visit, and physician expectations are rising. FDB Script Agent extends ambient AI automation beyond documentation into prescribing by interpreting physician intent from the encounter and assembling the codified prescription elements needed by the EHR.

Tebra integrated Script Agent into its Tebra AI Note Assist, Tebra’s AI-powered clinical documentation workflow for independent ambulatory practices.

“Prescribing is one of the most important moments in care, but it still buries clinicians in administrative work,” said David Delaney, MD, president of FDB. “By capturing prescriptions directly from the ambient exam-room conversation and grounding them in FDB’s trusted medication intelligence, Script Agent turns that dialogue into a structured prescription ready for review. This lowers the administrative burden of prescribing while keeping clinicians in control.”

Early Tebra users report the AI Note Assist feature using Script Agent is intuitive and reduces prescribing-related administrative effort while preserving confidence in the review process.

“Independent practices are being asked to do more with fewer resources, and every minute spent on administrative work is time taken away from patient care,” said Kyle Ryan, Tebra chief product and technology officer. “We’re excited to partner with FDB to deliver AI-powered prescription review that simplifies prescribing workflows and reduces operational burden. These capabilities, as well as FDB’s trusted, clinically validated content, drove our decision to collaborate and help advance Tebra’s broader mission of equipping independent providers with advanced technology to make everyday healthcare operations more efficient and effective.”

Script Agent also supports FDB’s broader prescription intelligence strategy. Once a clinician approves a prescription, FDB Vela™, FDB’s cloud-native ePrescribing network, can help carry it through the next steps of the medication journey, connecting prescribers, payers, pharmacies and patients.

The Tebra deployment of Script Agent marks the first step in FDB’s broader roadmap for AI-powered prescription intelligence, designed to reduce administrative burden while keeping clinicians at the center of prescribing.

About FDB

FDB (First Databank) delivers clinically robust, AI-enabled and workflow-integrated medication intelligence that is intuitive, patient-specific, and actionable. Our solutions enable more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline medication workflow operations, and enhance health outcomes. Our comprehensive medication intelligence and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB’s solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health

The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

About Tebra

Tebra is the only all-in-one EHR+ platform built exclusively for independent healthcare practices. Designed to replace the clunky, fragmented tools built for corporate systems, Tebra connects EHR software, billing, automation, telehealth solutions, and marketing — so providers can spend less time on admin and more time with patients. More than 42,000 private practices trust Tebra to streamline operations, increase revenue, and reduce burnout — helping clinicians leave work on time and rediscover their purpose. Learn more at www.tebra.com.

Media Contact

Supreme Communications for FDB

FDBPR@supremecomms.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/fdb-moves-ambient-listening-beyond-notes-with-ai-powered-prescribing-agent-302858338.html

SOURCE FDB (First Databank)

Continue Reading

Technology

Ridero Raises $2.7 Million to Tackle Vehicle Affordability Through AI-Powered Financial Infrastructure

Published

on

By

Backed by RiverPark Ventures, NY Ventures, Green Egg Ventures, Blackpoint Capital, and Potamkin Ventures, Ridero is expanding access to flexible vehicle financing.

NEW YORK, Nov. 9, 2026 /PRNewswire/ — Ridero, an AI-powered automotive financial infrastructure company, today announced $2.7 million in total pre-seed funding, with backing from RiverPark Ventures, NY Ventures, Green Egg Ventures, Blackpoint Capital, and Potamkin Ventures.

The funding will accelerate Ridero’s mission to address the growing vehicle affordability crisis by enabling financial institutions and automotive retailers to offer more flexible financing options at scale.

As vehicle prices and financing costs continue to pressure American households, traditional automotive financing products have struggled to keep pace with changing consumer needs. Ridero is building the technology infrastructure to expand access to alternatives to conventional auto loans, including new- and used-vehicle leasing and balloon financing.

“Millions of vehicles have historically been difficult to lease because the financial infrastructure needed to support them at scale hasn’t existed,” said Brock Thompson, Co-Founder and CEO of Ridero. “We’re building that infrastructure to give lenders and dealers more ways to make vehicles affordable and accessible,” said Natalie Williams, Co-Founder and CTO of Ridero.

Ridero’s platform combines AI-powered deal structuring, risk analytics, and automated lender connectivity to help financial institutions launch, distribute, and manage residual-based financing products.

The company’s technology is already in use at dealerships across the Northeast and Southern United States. Ridero has also established a strategic partnership with Auto Financial Group (AFG) to expand access to residual-based financing products and integrated with Tekion to bring its financing capabilities into existing dealership workflows.

Ridero is advancing additional strategic partnerships and technology integrations with financial institutions and automotive technology providers.

The funding will support continued product development, expansion of institutional partnerships, and growth of Ridero’s team.

About Ridero

Ridero is an AI-powered financial infrastructure company modernizing automotive finance. Its platform connects financial institutions and automotive retailers, enabling the launch, distribution, and management of flexible vehicle financing products, including new- and used-vehicle leasing and balloon financing.

Ridero was founded by Brock Thompson and Natalie Williams, who bring complementary backgrounds in institutional investing and artificial intelligence. Thompson previously worked at The Carlyle Group and The Amherst Group, while Williams came from Capstone Investment Advisors and UBS. Both founders attended Columbia University together.

Website: ridero.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/ridero-raises-2-7-million-to-tackle-vehicle-affordability-through-ai-powered-financial-infrastructure-302933733.html

SOURCE Ridero

Continue Reading

Technology

OpenHear BM420 Named a CES® 2027 Innovation Awards® Honoree

Published

on

By

Recognized in the Accessibility & Longevity category, the open-ear bone conduction hearing aid reflects Shokz’s expanding expertise in hearing care

AUSTIN, Texas, Nov. 9, 2026 /PRNewswire/ — Shokz, a pioneer in open-ear audio technology, today announced that OpenHear BM420 has been named a CES® 2027 Innovation Awards® Honoree in the Accessibility & Longevity category. Developed by Shokz’s affiliated professional hearing-care company ShokzHear, the device reflects the application of Shokz’s bone conduction expertise to hearing solutions designed with comfort, accessibility and everyday wearability in mind.

OpenHear BM420 is a professionally fitted, non-surgical bone conduction hearing aid designed to provide an alternative to traditional in-ear hearing aids and implantable bone conduction solutions. Its open-ear design keeps the ear canal unobstructed for comfort during extended wear, while individually adjustable hearing settings, directional microphones and background noise reduction help improve speech clarity in everyday environments.

“In hearing care, performance matters, but so does whether people feel comfortable wearing a device day after day,” said Fengyun Liao, Director of ShokzHear. “OpenHear BM420 brings our experience in open-ear bone conduction technology to that challenge, offering an alternative designed around both hearing assistance and everyday comfort. We’re honored to have this approach recognized by the CES Innovation Awards®.”

This recognition comes as Shokz prepares for CES 2027, where the company will showcase continued innovation in open-ear technology, including expanding applications beyond traditional audio.

OpenHear BM420 will be available beginning November 20, 2026, in the U.S. through participating hearing centers, ENT clinics and hospitals.

The CES Innovation Awards® program, owned and produced by the Consumer Technology Association (CTA)®, is an annual competition recognizing outstanding design and engineering in consumer technology. Entries are evaluated by a panel of industry experts, including engineers, designers and members of the media. The 2027 honorees, including product descriptions and images, can be found at ces.tech/ces-innovation-awards.

To learn more about Shokz, ShokzHear, OpenHear BM420 or the complete OpenHear Series, visit ShokzHear.com or follow @ShokzHear on Instagram, LinkedIn and YouTube.

About ShokzHear
ShokzHear is an affiliated company of Shokz, a global leader in bone conduction technology and open-ear acoustics. Drawing on more than a decade of innovation in consumer audio, ShokzHear is dedicated to advancing professional hearing care through accessible and comfortable hearing solutions, leveraging its expertise across both bone conduction and air conduction technologies. Its OpenHear series combines innovative acoustic engineering with everyday wearability, helping eligible individuals with hearing loss experience a different, more comfortable way to hear. Learn more about the brand at ShokzHear.com.

About CES®
CES is the most powerful tech event in the world – the proving ground for breakthrough technologies and global innovators. This is where the world’s biggest brands do business and meet new partners, and the sharpest innovators hit the stage. Owned and produced by the Consumer Technology Association (CTA)®, CES features every aspect of the tech sector. CES 2027 takes place Jan. 6-9, 2027, in Las Vegas. Learn more at CES.tech and follow CES on social.

The CES® Innovation Awards® are based upon descriptive materials submitted to the judges. CTA did not verify the accuracy of any submission or of any claims made and did not test the item to which the award was given.

View original content to download multimedia:https://www.prnewswire.com/news-releases/openhear-bm420-named-a-ces-2027-innovation-awards-honoree-302933652.html

SOURCE SHOKZ

Continue Reading

Technology

Bankers Expect Higher Funding Costs as Outlook for Loan Demand Softens

Published

on

By

ARLINGTON, Va., Nov. 9, 2026 /PRNewswire/ — Bank executives expect a tougher operating environment over the next year, with continued pressure on funding and little improvement in loan demand, according to a survey by fintech IntraFi.

Eighty-seven percent of respondents expect funding costs to increase in the next 12 months, up 84 points from the third quarter of 2025.

“Bankers are facing pressure on both sides of the balance sheet,” said Mark Jacobsen, CEO and cofounder of IntraFi. “The challenge is how to pursue growth without sacrificing profitability or stretching balance sheets. That puts a premium on disciplined pricing, strong customer relationships, and flexibility in how banks fund their business.”

IntraFi’s third quarter Bank Executive Business Outlook Survey was conducted online from October 5 to October 19, 2026, and includes responses from 411 bank CEOs, presidents, CFOs, and COOs nationwide.

Bond market volatility is also shaping bankers’ outlook. Over the next 12 months, 58% said the most significant potential effect of current long-term interest rates and bond market volatility on their securities portfolios would be higher funding costs or pressure on net interest margins. Another 16% cited further unrealized losses that could limit capital flexibility.

Other key findings

Balance sheet strategy: 47% are maintaining their current strategies, while 22% are accepting lower securities balances to make room for loans or cash and liquidity.Economy: 83% expect economic conditions to worsen or remain unchanged over the next 12 months.Access to capital: 78% expect access to capital to remain unchanged.Mortgages: 74% are not pursuing products or programs to help homeowners locked into low mortgage rates move or upgrade their homes.

Download the full report.

About IntraFi

A trusted partner chosen by more than 3,000 financial services companies, IntraFi defines success not by the volume of transactions it enables, but by the quality of relationships it forms. Its network, established over 20 years ago, connects institutions of all sizes to help participants build stronger relationships with their customers, fund more loans, seamlessly manage their liquidity needs, and earn fee income.

The network brings scale, giving each participant access to tens of billions of dollars in funding, the highest per-depositor and per-bank capacity, and the peace of mind of being able to make large-dollar placements.

View original content:https://www.prnewswire.com/news-releases/bankers-expect-higher-funding-costs-as-outlook-for-loan-demand-softens-302933750.html

SOURCE IntraFi

Continue Reading

Trending